SD Biosensor Inc (137310) - Total Liabilities
Based on the latest financial reports, SD Biosensor Inc (137310) has total liabilities worth ₩914.08 Billion KRW (≈ $619.46 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SD Biosensor Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how SD Biosensor Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of SD Biosensor Inc to evaluate short-term liquidity relative to the company's equity base.
SD Biosensor Inc Competitors by Total Liabilities
The table below lists competitors of SD Biosensor Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Lubei Chemical Co Ltd
SHG:600727
|
China | CN¥5.68 Billion |
|
Beijing Trust Far Tech
SHE:300231
|
China | CN¥815.28 Million |
|
ForFarmers NV
AS:FFARM
|
Netherlands | €672.00 Million |
|
Insteel Industries Inc
NYSE:IIIN
|
USA | $97.29 Million |
|
Zhejiang Jasan Holding Group Co Ltd
SHG:603558
|
China | CN¥1.57 Billion |
|
Svolder AB (publ)
ST:SVOL-B
|
Sweden | Skr109.50 Million |
|
Wuxi Acryl Technology Co Ltd
SHG:603722
|
China | CN¥262.59 Million |
|
Merlin, Inc.
NASDAQ:MRLN
|
USA | $619.23 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down SD Biosensor Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of SD Biosensor Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SD Biosensor Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SD Biosensor Inc (2019–2024)
The table below shows the annual total liabilities of SD Biosensor Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩956.18 Billion ≈ $647.99 Million |
-0.12% |
| 2023-12-31 | ₩957.28 Billion ≈ $648.74 Million |
+203.76% |
| 2022-12-31 | ₩315.14 Billion ≈ $213.57 Million |
-60.69% |
| 2021-12-31 | ₩801.72 Billion ≈ $543.32 Million |
+13.87% |
| 2020-12-31 | ₩704.10 Billion ≈ $477.16 Million |
+2113.84% |
| 2019-12-31 | ₩31.80 Billion ≈ $21.55 Million |
-- |
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volum… Read more